Money is moving into cannabis stocks at a pace the sector hasn't seen in years. The AdvisorShares Pure US Cannabis ETF (MSOS) climbed to its highest levels of 2026, with a one-year net asset value return of 103.7% through May 31 - more than double the North American Marijuana Index's 36.9% gain and well ahead of the S&P 500's 29.8% return. As of June 5, the fund held $1.13 billion in assets, and the timing is not incidental: a DEA administrative hearing set for June 29 could determine whether adult-use cannabis products join medical marijuana on the path to Schedule III.
Trulieve Cannabis, the ETF's largest holding at roughly 30% of assets, began trading on the NYSE under the ticker TRLV this week, a milestone that required the company to first separate its medical cannabis operations from its adult-use business to satisfy exchange listing standards. That kind of structural surgery isn't cosmetic - it reflects how seriously multi-state operators are now treating uplisting eligibility, since a senior exchange listing opens doors to institutional capital, broader analyst coverage, and easier access to banking relationships that federally illegal status has long restricted. On the operations side, that same push toward legitimacy and infrastructure upgrades is playing out at the store level too, where operators evaluating a point of sale cannabis dispensary virginia system are weighing the same questions multi-state operators face on Wall Street: can the technology keep pace with a market moving toward mainstream financial integration, compliant recordkeeping, and tighter seed-to-sale accountability? point of sale cannabis dispensary virginia
What the Schedule III Shift Actually Changes
Here's the mechanism worth understanding: Schedule III reclassification does not legalize cannabis nationally, and it does not touch state licensing regimes, METRC tracking mandates, or local zoning rules. What it does is remove the 280E tax penalty for state-licensed medical operators, meaning companies can finally deduct ordinary business expenses - payroll, rent, interest - the way any other regulated business would. That's a real balance-sheet event, not a symbolic one. AdvisorShares has pointed to improved earnings, stronger free cash flow, and better access to capital and institutional investors as the practical downstream effects. Roth Capital called the rescheduling order "extremely favorable," citing benefits across taxation, capital markets access, and future uplisting potential. None of that changes overnight, though. The June 29 hearing is expected to run through mid-July, and administrative proceedings of this scale rarely resolve cleanly on the first pass.
Capital Access Is Already Moving
Cresco Labs didn't wait for a final ruling. The company secured a $50 million revolving credit facility from Needham Bank this week, with CEO Charlie Bachtell describing it as a non-dilutive tool to fund acquisitions while positioning the company for U.S. capital markets access and a possible future uplisting. That's the kind of financing move dispensary operators and wholesalers should watch closely - it signals lenders are getting more comfortable underwriting cannabis credit risk ahead of federal clarity, not after it. Tilray Brands, while outside the MSOS portfolio, has flagged similar intentions, saying proceeds from a recent at-the-market offering may fund acquisitions and expansion tied to anticipated reform.
Where the Upside - and the Risk - Actually Sits
Trulieve gets the headlines, but it isn't where analysts see the biggest re-rating potential. Verano carries an estimated 195% upside per Koyfin data, followed by Jushi Holdings near 183% and Cresco Labs close to 99%. Among the larger holdings, Green Thumb Industries stands out with roughly 70% upside, ahead of both Trulieve and Curaleaf. Retail sentiment on platforms like Stocktwits has run "extremely bullish" on MSOS, Trulieve, and Green Thumb amid heavy message volume.
Fair enough - the enthusiasm has fundamentals behind it. But operators and investors alike should remember that administrative hearings can stall, get appealed, or produce narrower outcomes than markets are pricing in. Rescheduling doesn't touch state-level compliance burdens: lab testing requirements, compliant packaging standards, age-verification protocols, and advertising restrictions all remain squarely in state hands regardless of what the DEA decides this month. For dispensary owners managing budroom inventory and compliance logs day to day, the bigger federal story is real, but the daily grind of running a licensed retail operation doesn't change until the ink is dry.
